Emerging roles for hyaluronidase in cancer metastasis and therapy

Advances in Cancer Research

Volumn 123, Issue , 2014, Pages 1-34

  McAtee, Caitlin O ^a   Barycki, Joseph J ^a   Simpson, Melanie A ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Cancer therapy; Hyaluronan; Hyaluronidase; Metastasis; Tumor biology; Tumor imaging

Indexed keywords

GLYCYRRHIZIC ACID; HYALURONIC ACID; HYALURONIDASE; HYALURONIDASE 1; HYALURONIDASE 2; HYALURONIDASE 3; HYALURONIDASE 4; INDOLE DERIVATIVE; OLIGOMER; POLYMER; POLYSTYRENESULFONIC ACID; PROTEIN PH 20; UNCLASSIFIED DRUG; HYALURONOGLUCOSAMINIDASE;

ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL MOTILITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG CANCER; METASTASIS; MOLECULAR WEIGHT; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TRANSPORT VESICLE; TUMOR INVASION; UROGENITAL TRACT CANCER; ALTERNATIVE RNA SPLICING; ANIMAL; CELL MOTION; CHEMISTRY; CONFORMATION; DISEASE COURSE; FIBROBLAST; METABOLISM; MOLE RAT; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RAT;

ALTERNATIVE SPLICING; ANIMALS; CELL MOVEMENT; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MOLE RATS; MOLECULAR CONFORMATION; MOLECULAR WEIGHT; NEOPLASM METASTASIS; NEOPLASMS; POLYMERS; PROGNOSIS; RATS;

EID: 84904860939     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800092-2.00001-0     Document Type: Chapter

References (122)

1. Aaltomaa S., Lipponen P., Tammi R., Tammi M., Viitanen J., Kankkunen J.P., et al. Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urologia Internationalis 2002, 69:266-272.
2. Andre B., Duterme C., Van Moer K., Mertens-Strijthagen J., Jadot M., Flamion B. Hyal2 is a glycosylphosphatidylinositol-anchored, lipid raft-associated hyaluronidase. Biochemical and Biophysical Research Communications 2011, 411:175-179.
3. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313.
4. Atmuri V., Martin D.C., Hemming R., Gutsol A., Byers S., Sahebjam S., et al. Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biology 2008, 27:653-660.
5. Beech D.J., Madan A.K., Deng N. Expression of PH-20 in normal and neoplastic breast tissue. Journal of Surgical Research 2002, 103:203-207.
6. Benitez A., Yates T.J., Lopez L.E., Cerwinka W.H., Bakkar A., Lokeshwar V.B. Targeting hyaluronidase for cancer therapy: Antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Research 2011, 71:4085-4095.
7. Berdiaki A., Nikitovic D., Tsatsakis A., Katonis P., Karamanos N.K., Tzanakakis G.N. bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. Biochimica et Biophysica Acta 2009, 1790:1258-1265.
8. Bharadwaj A.G., Goodrich N.P., McAtee C.O., Haferbier K., Oakley G.G., Wahl J.K., et al. Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling. Experimental Cell Research 2011, 317:1214-1225.
9. Bharadwaj A.G., Kovar J.L., Loughman E., Elowsky C., Oakley G.G., Simpson M.A. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. American Journal of Pathology 2009, 174:1027-1036.
10. Bharadwaj A.G., Rector K., Simpson M.A. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. Journal of Biological Chemistry 2007, 282:20561-20572.
11. Botzki A., Rigden D.J., Braun S., Nukui M., Salmen S., Hoechstetter J., et al. L-ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor. X-ray structure and molecular modeling of enzyme-inhibitor complexes. Journal of Biological Chemistry 2004, 279:45990-45997.
12. Bouga H., Tsouros I., Bounias D., Kyriakopoulou D., Stavropoulos M.S., Papageorgakopoulou N., et al. Involvement of hyaluronidases in colorectal cancer. BMC Cancer 2010, 10:499.
13. Bourguignon L.Y., Wong G., Earle C.A., Xia W. Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFkappaB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken) 2011, 68:671-693.
14. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. Journal of Biological Chemistry 2000, 275:1829-1838.
15. Camenisch T.D., Spicer A.P., Brehm-Gibson T., Biesterfeldt J., Augustine M.L., Calabro A., et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. Journal of Clinical Investigation 2000, 106:349-360. (see comments).
16. Chang N.S. Transforming growth factor-beta1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase Hyal-2 in L929 fibroblasts. BMC Cell Biology 2002, 3:8.
17. Chang J.Y., He R.Y., Lin H.P., Hsu L.J., Lai F.J., Hong Q., et al. Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Experimental Biology and Medicine (Maywood, N.J.) 2010, 235:796-804.
18. Chao K.L., Muthukumar L., Herzberg O. Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis. Biochemistry 2007, 46:6911-6920.
19. Chen S.T., Chuang J.I., Wang J.P., Tsai M.S., Li H., Chang N.S. Expression of WW domain-containing oxidoreductase WOX1 in the developing murine nervous system. Neuroscience 2004, 124:831-839.
20. Cheng X.B., Sato N., Kohi S., Yamaguchi K. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One 2013, 8:e80765.
21. Chi A., Shirodkar S.P., Escudero D.O., Ekwenna O.O., Yates T.J., Ayyathurai R., et al. Molecular characterization of kidney cancer: Association of hyaluronic acid family with histological subtypes and metastasis. Cancer 2012, 118:2394-2402.
22. Chib R., Raut S., Fudala R., Chang A., Mummert M., Rich R., et al. FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer. Current Pharmaceutical Biotechnology 2013, 14:470-474.
23. Craig E.A., Parker P., Camenisch T.D. Size-dependent regulation of Snail2 by hyaluronan: Its role in cellular invasion. Glycobiology 2009, 19:890-898.
24. Csoka A.B., Frost G.I., Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biology 2001, 20:499-508.
25. Dang S., Peng Y., Ye L., Wang Y., Qian Z., Chen Y., et al. Stimulation of TLR4 by LMW-HA induces metastasis in human papillary thyroid carcinoma through CXCR7. Clinical & Developmental Immunology 2013, 2013:712561.
26. Danilkovitch-Miagkova A., Duh F.M., Kuzmin I., Angeloni D., Liu S.L., Miller A.D., et al. Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4580-4585.
27. de Sa V.K., Canavez F.C., Silva I.A., Srougi M., Leite K.R. Isoforms of hyaluronidases can be a predictor of a prostate cancer of good prognosis. Urologic Oncology 2009, 27:377-381.
28. de Sa V.K., Carvalho L., Gomes A., Alarcao A., Silva M.R., Couceiro P., et al. Role of the extracellular matrix in variations of invasive pathways in lung cancers. Brazilian Journal of Medical and Biological Research 2013, 46:21-31.
29. de Sa V.K., Olivieri E., Parra E.R., Ab'Saber A.M., Takagaki T., Soares F.A., et al. Hyaluronidase splice variants are associated with histology and outcome in adenocarcinoma and squamous cell carcinoma of the lung. Human Pathology 2012, 43:675-683.
30. Deed R., Rooney P., Kumar P., Norton J.D., Smith J., Freemont A.J., et al. Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan. International Journal of Cancer 1997, 71:251-256.
31. Duh F.M., Dirks C., Lerman M.I., Miller A.D. Amino acid residues that are important for Hyal2 function as a receptor for jaagsiekte sheep retrovirus. Retrovirology 2005, 2:59.
32. Duterme C., Mertens-Strijthagen J., Tammi M., Flamion B. Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. Journal of Biological Chemistry 2009, 284:33495-33508.
33. Eissa S., Shehata H., Mansour A., Esmat M., El-Ahmady O. Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer. Medical Oncology 2012, 29:3345-3351.
34. Eissa S., Swellam M., Shehata H., El-Khouly I.M., El-Zayat T., El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. Journal of Urology 2010, 183:493-498.
35. Eissa S., Zohny S.F., Shehata H.H., Hegazy M.G., Salem A.M., Esmat M. Urinary retinoic acid receptor-beta2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clinical Biochemistry 2012, 45:402-407.
36. Ekici S., Cerwinka W.H., Duncan R., Gomez P., Civantos F., Soloway M.S., et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. International Journal of Cancer 2004, 112:121-129.
37. Enegd B., King J.A., Stylli S., Paradiso L., Kaye A.H., Novak U. Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery 2002, 50:1311-1318.
38. Fraser J.R., Laurent T.C., Laurent U.B. Hyaluronan: Its nature, distribution, functions and turnover. Journal of Internal Medicine 1997, 242:27-33.
39. Godin D.A., Fitzpatrick P.C., Scandurro A.B., Belafsky P.C., Woodworth B.A., Amedee R.G., et al. PH20: A novel tumor marker for laryngeal cancer. Archives of Otolaryngology Head & Neck Surgery 2000, 126:402-404.
40. Gomez C.S., Gomez P., Knapp J., Jorda M., Soloway M.S., Lokeshwar V.B. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: Predictors of biochemical recurrence. Journal of Urology 2009, 182:1350-1356.
41. Harada H., Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. Journal of Biological Chemistry 2007, 282:5597-5607.
42. Hemming R., Martin D.C., Slominski E., Nagy J.I., Halayko A.J., Pind S., et al. Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells. Glycobiology 2008, 18:280-289.
43. Hofinger E.S., Spickenreither M., Oschmann J., Bernhardt G., Rudolph R., Buschauer A. Recombinant human hyaluronidase Hyal-1: Insect cells versus Escherichia coli as expression system and identification of low molecular weight inhibitors. Glycobiology 2007, 17:444-453.
44. Honda T., Kaneiwa T., Mizumoto S., Sugahara K., Yamada S. Hyaluronidases have strong hydrolytic activity toward chondroitin 4-sulfate comparable to that for hyaluronan. Biomolecules 2012, 2:549-563.
45. Hsu L.J., Schultz L., Hong Q., Van Moer K., Heath J., Li M.Y., et al. Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. Journal of Biological Chemistry 2009, 284:16049-16059.
46. Isoyama T., Thwaites D., Selzer M.G., Carey R.I., Barbucci R., Lokeshwar V.B. Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases. Glycobiology 2006, 16:11-21.
47. Itano N., Sawai T., Atsumi F., Miyaishi O., Taniguchi S., Kannagi R., et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. Journal of Biological Chemistry 2004, 279:18679-18687.
48. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. Journal of Biological Chemistry 1999, 274:25085-25092.
49. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. International Journal of Cancer 2002, 102:212-219.
50. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
51. Kaessler A., Olgen S., Jose J. Autodisplay of catalytically active human hyaluronidase hPH-20 and testing of enzyme inhibitors. European Journal of Pharmaceutical Sciences 2011, 42:138-147.
52. Kaneiwa T., Miyazaki A., Kogawa R., Mizumoto S., Sugahara K., Yamada S. Identification of amino acid residues required for the substrate specificity of human and mouse chondroitin sulfate hydrolase (conventional hyaluronidase-4). Journal of Biological Chemistry 2012, 287:42119-42128.
53. Kaneiwa T., Mizumoto S., Sugahara K., Yamada S. Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence. Glycobiology 2010, 20:300-309.
54. Kelley L.A., Sternberg M.J. Protein structure prediction on the web: A case study using the Phyre server. Nature Protocols 2009, 4:363-371.
55. Kim S.W., Oh K.T., Youn Y.S., Lee E.S. Hyaluronated nanoparticles with pH- and enzyme-responsive drug release properties. Colloids and Surfaces. B, Biointerfaces 2014, 116C:359-364.
56. Kolliopoulos C., Bounias D., Bouga H., Kyriakopoulou D., Stavropoulos M., Vynios D.H. Hyaluronidases and their inhibitors in the serum of colorectal carcinoma patients. Journal of Pharmaceutical and Biomedical Analysis 2013, 83:299-304.
57. Kosaki R., Watanabe K., Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Research 1999, 59:1141-1145.
58. Kovar J.L., Johnson M.A., Volcheck W.M., Chen J., Simpson M.A. Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. American Journal of Pathology 2006, 169:1415-1426.
59. Kramer M.W., Escudero D.O., Lokeshwar S.D., Golshani R., Ekwenna O.O., Acosta K., et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011, 117:1197-1209.
60. Kramer M.W., Golshani R., Merseburger A.S., Knapp J., Garcia A., Hennenlotter J., et al. HYAL-1 hyaluronidase: A potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. European Urology 2010, 57:86-93.
61. Langevin S.M., Koestler D.C., Christensen B.C., Butler R.A., Wiencke J.K., Nelson H.H., et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: An epigenome-wide association study. Epigenetics 2012, 7:291-299.
62. Laurent T.C., Laurent U.B., Fraser J.R. The structure and function of hyaluronan: An overview. Immunology and Cell Biology 1996, 74:A1-A7.
63. Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nature Cell Biology 2002, 4:399-407.
64. Lepperdinger G., Strobl B., Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. Journal of Biological Chemistry 1998, 273:22466-22470.
65. Li R., Todd N.W., Qiu Q., Fan T., Zhao R.Y., Rodgers W.H., et al. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clinical Cancer Research 2007, 13:482-487.
66. Li Y., Wang D., Wang L., Yu J., Du D., Chen Y., et al. Distinct genomic aberrations between low-grade and high-grade gliomas of Chinese patients. PLoS One 2013, 8:e57168.
67. Liu S.L., Duh F.M., Lerman M.I., Miller A.D. Role of virus receptor Hyal2 in oncogenic transformation of rodent fibroblasts by sheep betaretrovirus env proteins. Journal of Virology 2003, 77:2850-2858.
68. Lokeshwar V.B., Cerwinka W.H., Isoyama T., Lokeshwar B.L. HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor. Cancer Research 2005, 65:7782-7789.
69. Lokeshwar V.B., Estrella V., Lopez L., Kramer M., Gomez P., Soloway M.S., et al. HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: A negative regulator of bladder cancer. Cancer Research 2006, 66:11219-11227.
70. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., Forgacs E., Minna J.D., Block N.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. Journal of Biological Chemistry 2001, 276:11922-11932.
71. Lokeshwar V.B., Schroeder G.L., Carey R.I., Soloway M.S., Iida N. Regulation of hyaluronidase activity by alternative mRNA splicing. Journal of Biological Chemistry 2002, 277:33654-33663.
72. Madan A.K., Pang Y., Wilkiemeyer M.B., Yu D., Beech D.J. Increased hyaluronidase expression in more aggressive prostate adenocarcinoma. Oncology Reports 1999, 6:1431-1433.
73. Madan A.K., Yu K., Dhurandhar N., Cullinane C., Pang Y., Beech D.J. Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncology Reports 1999, 6:607-609.
74. McAtee C. O., Berkebile A., Elowsky C., Fangman T., Wahl J. K., Khalimonchuk O., et al. Hyaluronidase Hyal1 increases tumor cell proliferation and motility through accelerated vesicle trafficking. Submitted.
75. McCarthy J.B., Turley E.A., Wilson C.M., Price M., Bullard K.M., Beck M. Hyaluronan biosynthesis in prostate carcinoma growth and metastasis. Hyaluronan and Tumors 2005, Matrix Biology Institute, Edgewater, NJ, Chapter 4. E.A. Balasz, V.C. Hascall (Eds.).
76. Mok H., Jeong H., Kim S.J., Chung B.H. Indocyanine green encapsulated nanogels for hyaluronidase activatable and selective near infrared imaging of tumors and lymph nodes. Chemical Communications (Cambridge, England) 2012, 48:8628-8630.
77. Mu W., Rana S., Zoller M. Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia 2013, 15:875-887.
78. Novak U., Stylli S.S., Kaye A.H., Lepperdinger G. Hyaluronidase-2 overexpression accelerates intracerebral but not subcutaneous tumor formation of murine astrocytoma cells. Cancer Research 1999, 59:6246-6250.
79. Nykopp T.K., Rilla K., Sironen R., Tammi M.I., Tammi R.H., Hamalainen K., et al. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: Inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 2009, 9:143.
80. Nykopp T.K., Rilla K., Tammi M.I., Tammi R.H., Sironen R., Hamalainen K., et al. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. BMC Cancer 2010, 10:512.
81. Ohnuma S., Miura K., Horii A., Fujibuchi W., Kaneko N., Gotoh O., et al. Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery 2009, 145:57-68.
82. Olgen S., Kaessler A., Kilic-Kurt Z., Jose J. Investigation of aminomethyl indole derivatives as hyaluronidase inhibitors. Zeitschrift für Naturforschung C 2010, 65:445-450.
83. Olgen S., Kaessler A., Nebioglu D., Jose J. New potent indole derivatives as hyaluronidase inhibitors. Chemical Biology & Drug Design 2007, 70:547-551.
84. Patel S., Turner P.R., Stubberfield C., Barry E., Rohlff C.R., Stamps A., et al. Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. International Journal of Cancer 2002, 97:416-424.
85. Poola I., Abraham J., Marshalleck J.J., Yue Q., Lokeshwar V.B., Bonney G., et al. Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clinical Cancer Research 2008, 14:1274-1280.
86. Posey J.T., Soloway M.S., Ekici S., Sofer M., Civantos F., Duncan R.C., et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Research 2003, 63:2638-2644.
87. Proulx S.T., Detmar M. Molecular mechanisms and imaging of lymphatic metastasis. Experimental Cell Research 2013, pii: S0014-4827(13)00117-1. 10.1016/j.yexcr.2013.03.009.
88. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
89. Puissant E., Gilis F., Dogne S., Flamion B., Jadot M., Boonen M. Subcellular trafficking and activity of Hyal-1 and its processed forms in murine macrophages. Traffic (Copenhagen, Denmark) 2014, 15:500-515.
90. Reitinger S., Mullegger J., Greiderer B., Nielsen J.E., Lepperdinger G. Designed human serum hyaluronidase 1 variant, HYAL1DeltaL, exhibits activity up to pH5.9. Journal of Biological Chemistry 2009, 284:19173-19177.
91. Rich R.M., Mummert M., Foldes-Papp Z., Gryczynski Z., Borejdo J., Gryczynski I., et al. Detection of hyaluronidase activity using fluorescein labeled hyaluronic acid and fluorescence correlation spectroscopy. Journal of Photochemistry and Photobiology B 2012, 116:7-12.
92. Rilla K., Pasonen-Seppanen S., Deen A.J., Koistinen V.V., Wojciechowski S., Oikari S., et al. Hyaluronan production enhances shedding of plasma membrane-derived microvesicles. Experimental Cell Research 2013, 319:2006-2018.
93. Rooney P., Kumar S., Ponting J., Wang M. The role of hyaluronan in tumour neovascularization (review). International Journal of Cancer 1995, 60:632-636.
94. Saito T., Kawana H., Azuma K., Toyoda A., Fujita H., Kitagawa M., et al. Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane. International Journal of Oncology 2011, 39:1311-1320.
95. Sharma R., Wang W., Rasmussen J.C., Joshi A., Houston J.P., Adams K.E., et al. Quantitative imaging of lymph function. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H3109-H3118.
96. Shiftan L., Israely T., Cohen M., Frydman V., Dafni H., Stern R., et al. Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. Cancer Research 2005, 65:10316-10323.
97. Shiftan L., Neeman M. Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent. Contrast Media & Molecular Imaging 2006, 1:106-112.
98. Siiskonen H., Poukka M., Tyynela-Korhonen K., Sironen R., Pasonen-Seppanen S. Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma. BMC Cancer 2013, 13:181.
99. Simpson M.A. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. American Journal of Pathology 2006, 169:247-257.
100. Simpson M.A., Wilson C.M., McCarthy J.B. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. American Journal of Pathology 2002, 161:849-857.
101. Sugahara K.N., Hirata T., Tanaka T., Ogino S., Takeda M., Terasawa H., et al. Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Research 2008, 68:7191-7199.
102. Tammi R., Rilla K., Pienimaki J.P., MacCallum D.K., Hogg M., Luukkonen M., et al. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. Journal of Biological Chemistry 2001, 276:35111-35122.
103. Tan J.X., Wang X.Y., Li H.Y., Su X.L., Wang L., Ran L., et al. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. International Journal of Cancer 2011, 128:1303-1315.
104. Tan J.X., Wang X.Y., Su X.L., Li H.Y., Shi Y., Wang L., et al. Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PLoS One 2011, 6:e22836.
105. Tian X., Azpurua J., Hine C., Vaidya A., Myakishev-Rempel M., Ablaeva J., et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013, 499:346-349.
106. Toida T., Ogita Y., Suzuki A., Toyoda H., Imanari T. Inhibition of hyaluronidase by fully O-sulfonated glycosaminoglycans. Archives of Biochemistry and Biophysics 1999, 370:176-182.
107. Toole B.P. Hyaluronan in morphogenesis. Journal of Internal Medicine 1997, 242:35-40.
108. Twarock S., Tammi M.I., Savani R.C., Fischer J.W. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. Journal of Biological Chemistry 2010, 285:23276-23284.
109. Tzellos T.G., Kyrgidis A., Vahtsevanos K., Triaridis S., Printza A., Klagas I., et al. Nodular basal cell carcinoma is associated with increased hyaluronan homeostasis. Journal of the European Academy of Dermatology and Venereology 2011, 25:679-687.
110. Udabage L., Brownlee G.R., Nilsson S.K., Brown T.J. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Experimental Cell Research 2005, 310:205-217.
111. Udabage L., Brownlee G.R., Stern R., Brown T.J. Inhibition of hyaluronan degradation by dextran sulphate facilitates characterisation of hyaluronan synthesis: An in vitro and in vivo study. Glycoconjugate Journal 2004, 20:461-471.
112. Urakawa H., Nishida Y., Knudson W., Knudson C.B., Arai E., Kozawa E., et al. Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. Journal of Orthopaedic Research 2012, 30:662-672.
113. Vigdorovich V., Strong R.K., Miller A.D. Expression and characterization of a soluble, active form of the jaagsiekte sheep retrovirus receptor, Hyal2. Journal of Virology 2005, 79:79-86.
114. Webber J.P., Spary L.K., Sanders A.J., Chowdhury R., Jiang W.G., Steadman R., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2014, 10.1038/onc.2013.560.
115. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research 2010, 70:9621-9630.
116. West D.C., Hampson I.N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228:1324-1326.
117. West D.C., Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Experimental Cell Research 1989, 183:179-196.
118. Yang C., Cao M., Liu H., He Y., Xu J., Du Y., et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. Journal of Biological Chemistry 2012, 287:43094-43107.
119. Yoffou P.H., Edjekouane L., Meunier L., Tremblay A., Provencher D.M., Mes-Masson A.M., et al. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. PLoS One 2011, 6:e20705.
120. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. International Journal of Cancer 1998, 77:396-401.
121. Zhang L., Bharadwaj A.G., Casper A., Barkley J., Barycki J.J., Simpson M.A. Hyaluronidase activity of human Hyal1 requires active site acidic and tyrosine residues. Journal of Biological Chemistry 2009, 284:9433-9442.
122. Zhang R.X., Zhu J.H., Fan J., Ji X.Q. Analysis of HYAL3 gene mutations in Chinese lung squamous cell carcinoma patients. Tumori 2013, 99:108-112.